Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities.

Area of Science:

• Molecular Biology
• Microbial Genomics
• Biotechnology

Background:

• CRISPR-Cas12a enzymes are programmable nucleases derived from microbial adaptive immune systems.
• The natural diversity of these systems remains largely unexplored, limiting their application potential.
• Existing Cas12a systems offer powerful genome editing but may have limitations in scope and targeting.

Purpose of the Study:

• To identify and characterize novel Type V-A CRISPR-Cas12a nucleases from diverse environmental metagenomes.
• To develop these newly identified systems into functional gene-editing platforms.
• To explore the potential of these novel nucleases for genome engineering and therapeutic applications.

Main Methods:

• Large-scale metagenomic analysis of environmental DNA samples.
• Bioinformatic identification and characterization of novel Cas12a variants.
• Biochemical assays to determine nuclease activity and protospacer adjacent motif (PAM) diversity.
• Testing of gene-editing activity in human cell lines.

Main Results:

• Identification of novel families of Type V-A CRISPR-Cas12a nucleases.
• Demonstration of extensive protein variation and programmability via single-guide RNA.
• Discovery of unexpected protospacer adjacent motif (PAM) diversity.
• Confirmation of nuclease activity in human cell lines, indicating therapeutic potential.

Conclusions:

• The identified novel Cas12a systems expand the toolkit for genome engineering.
• The diverse PAM recognition broadens the applicability of CRISPR-Cas12a technology.
• These systems, particularly those from uncultivated organisms, hold significant promise for gene and cell therapies.